Drugs / AstroStem
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03979898 | Jun 2017 → Apr 2019 | cerebral palsy | R-Bio | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03117738 | May 2017 → Jun 2019 | Alzheimer disease | Nature Cell Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04482413 | Feb 2023 → May 2024 | Alzheimer disease | Nature Cell Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AstroStem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03117738 ↗ |
| Known as | AdMSCs | “Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.” NCT04482413 ↗ |
| Modality | Cell therapy | “autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs)” NCT03979898 ↗ |
| Route | Intravenous | “AstroStem or placebo control will be administered via I.V. at Week 0.” NCT03117738 ↗ |